Literature DB >> 1748630

A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression.

A Seth1, E Alvarez, S Gupta, R J Davis.   

Abstract

The c-myc gene encodes a sequence-specific DNA-binding protein (c-Myc) that forms leucine zipper complexes and can act as a transcription factor. Growth factor stimulation of cells causes the phosphorylation of the c-Myc transcriptional activation domain at Ser62 within a proline-rich region that is highly conserved among members of the Myc family (Alvarez, E., Northwood, I.C., Gonzalez, F. A., Latour, D. A., Seth, A., Abate, C., Curran, T., and Davis, R. J. (1991) J. Biol. Chem. 266, 15277-15285). This phosphorylation site is a substrate for growth factor-regulated MAP kinases and for the cell cycle-dependent protein kinase p34cdc2. We report that serum treatment of cells results in a marked increase in the transactivation of gene expression mediated by the c-Myc transcriptional activation domain. A point mutation at the site of growth factor-stimulated phosphorylation (Ser62) decreases the serum induction of transactivation. These data indicate that the c-Myc transcriptional activation domain may be a direct target of signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748630

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

Review 1.  Nuclear protein phosphorylation and growth control.

Authors:  D W Meek; A J Street
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

Review 2.  Molecular signal integration. Interplay between serine, threonine, and tyrosine phosphorylation.

Authors:  J Posada; J A Cooper
Journal:  Mol Biol Cell       Date:  1992-06       Impact factor: 4.138

3.  Dexniguldipine hydrochloride, a protein-kinase-C-specific inhibitor, affects the cell cycle, differentiation, P-glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells.

Authors:  K K Patterson; B S Beckman; D M Klotz; C M Mallia; J R Jeter
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  The transactivation potential of a c-Myc N-terminal region (residues 92-143) is regulated by growth factor/Ras signaling.

Authors:  M S Colman; M C Ostrowski
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

5.  Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells. Evidence that this pathway is important in Kaposi cell growth.

Authors:  M C Amaral; S Miles; G Kumar; A E Nel
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

6.  Cloning and characterization of p97MAPK, a novel human homolog of rat ERK-3.

Authors:  A X Zhu; Y Zhao; D E Moller; J S Flier
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Glycosylation of the c-Myc transactivation domain.

Authors:  T Y Chou; C V Dang; G W Hart
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

8.  Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway.

Authors:  T W Schulte; M V Blagosklonny; L Romanova; J F Mushinski; B P Monia; J F Johnston; P Nguyen; J Trepel; L M Neckers
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein.

Authors:  Jin Shi; Peter K Vogt
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

10.  Transforming growth factor beta 1 inhibits mitogen-activated protein kinase induced by basic fibroblast growth factor in smooth muscle cells.

Authors:  E Berrou; M Fontenay-Roupie; R Quarck; F R McKenzie; S Lévy-Toledano; G Tobelem; M Bryckaert
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.